{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-017770","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.175572+00:00","generated_at":"2026-06-05T09:37:57.484518+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CERo Therapeutics secures $25M equity line with Arena; MD Anderson fund requests additional data before grant","bullets":["Enters purchase agreement with Arena for up to $25M of common stock; shares priced at 90% of Market Price.","Max advance per notice is lesser of 60% avg daily value traded (or 30% if after 8:30 ET) and $20M/$15M cap.","Commitment fee shares equal 500,000 divided by avg VWAP over 5 days pre-ELOC reg effectiveness.","MD Anderson's Cancer Focus Fund requested additional technical data; company expects to reapply short term, funding not assured.","Shares issued under Section 4(a)(2)/Reg D exemption; 4.99% ownership limitation applies."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-017770","json":"https://secwatch.observer/filing/0001213900-24-017770.json","markdown":"https://secwatch.observer/filing/0001213900-24-017770.md","text":"https://secwatch.observer/filing/0001213900-24-017770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017770/0001213900-24-017770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017770/ea0200582-8k_cerothera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:37:57.484518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d820db058f29197c9ce5240a4e8770991e3af68","claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Purchase Agreement with Arena Business Solutions Global SPC II, Ltd on behalf of and for the account of Segregated Portfolio #13 – SPC #13 valued at up to $25 million (effective 2024-02-23).","evidence_excerpt":"On February 23, 2024, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “ Company ”), entered into a purchase agreement (the “Purchase Agreement ”) with Arena Business Solutions Global SPC II, Ltd on behalf of and for the account of Segregated Portfolio #13 – SPC #13 (“ Arena ”), pursuant to which Arena has committed to purchase up to $25 million (the “ Commitment Amount ”) of the Company’s shares of common stock, par value $0.0001 per share (the “ Common Stock ”), subject to the satisfaction of the conditions in the Purchase Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017770/0001213900-24-017770-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Arena Business Solutions Global SPC II, Ltd on behalf of and for the account of Segregated Portfolio #13 – SPC #13"},{"label":"Value","value":"up to $25 million"},{"label":"Effective","value":"2024-02-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}